(BUSINESS WIRE)--Acumen Pharmaceuticals Inc. (www.acumenpharm.com) is a venture-backed, pre-clinical biotech company, focused on developing the first effective therapeutics and diagnostics for Alzheimer's disease and other memory-related disorders. Founded in 1996, Acumen owns or has licensed the critical patents underlying the ADDL mechanism now widely believed to cause Alzheimer's disease. In addition to an ELISA-based diagnostic, Acumen has three small molecule programs to stop ADDL-related diseases. NeuroVentures LLC and the Biotech Value Fund have made a seed investment in the Company.
Company: Acumen Pharmaceuticals, Inc.
Headquarters Address: 1309 Evergreen Court Glenview, IL 60025
Main Telephone: 415-281-1392
Type of Organization: Private
Industry: Health: Biotechnology
Key Executives: CEO: David Summa CSO: Grant Krafft
President Contact: David Summa Phone: 415-281-1392 Email: firstname.lastname@example.org
Chief Science Officer Contact: Grant Krafft Phone: 847-729-6687 Email: email@example.com
Contact: Acumen Pharmaceuticals, Inc.
Source: Acumen Pharmaceuticals, Inc.